|
|
Mechanism of insulin resistance in obesity: a role of ATP |
Jianping Ye() |
Shanghai Diabetes Institute, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai 200233, China |
|
|
Abstract Obesity increases the risk of type 2 diabetes through the induction of insulin resistance. The mechanism of insulin resistance has been extensively investigated for more than 60 years, but the essential pathogenic signal remains missing. Existing hypotheses include inflammation, mitochondrial dysfunction, hyperinsulinemia, hyperglucagonemia, glucotoxicity, and lipotoxicity. Drug discoveries based on these hypotheses are unsuccessful in the development of new medicines. In this review, multidisciplinary literature is integrated to evaluate ATP as a primary signal for insulin resistance. The ATP production is elevated in insulin-sensitive cells under obese conditions independent of energy demand, which we have named “mitochondrial overheating.” Overheating occurs because of substrate oversupply to mitochondria, leading to extra ATP production. The ATP overproduction contributes to the systemic insulin resistance through several mechanisms, such as inhibition of AMPK, induction of mTOR, hyperinsulinemia, hyperglucagonemia, and mitochondrial dysfunction. Insulin resistance represents a feedback regulation of energy oversupply in cells to control mitochondrial overloading by substrates. Insulin resistance cuts down the substrate uptake to attenuate mitochondrial overloading. The downregulation of the mitochondrial overloading by medicines, bypass surgeries, calorie restriction, and physical exercise leads to insulin sensitization in patients. Therefore, ATP may represent the primary signal of insulin resistance in the cellular protective response to the substrate oversupply. The prevention of ATP overproduction represents a key strategy for insulin sensitization.
|
Keywords
type 2 diabetes
energy expenditure
mitochondria
hyperinsulinemia
hyperglucagonemia
AMPK
|
Corresponding Author(s):
Jianping Ye
|
Just Accepted Date: 08 May 2021
Online First Date: 28 May 2021
Issue Date: 18 June 2021
|
|
1 |
J Ye. Mechanisms of insulin resistance in obesity. Front Med 2013; 7(1): 14–24
https://doi.org/10.1007/s11684-013-0262-6
pmid: 23471659
|
2 |
MA Sanchez-Garrido, M Tena-Sempere. Metabolic dysfunction in polycystic ovary syndrome: pathogenic role of androgen excess and potential therapeutic strategies. Mol Metab 2020; 35: 100937
https://doi.org/10.1016/j.molmet.2020.01.001
pmid: 32244180
|
3 |
M Roden, GI Shulman. The integrative biology of type 2 diabetes. Nature 2019; 576(7785): 51–60
https://doi.org/10.1038/s41586-019-1797-8
pmid: 31802013
|
4 |
I Nikolic, M Leiva, G Sabio. The role of stress kinases in metabolic disease. Nat Rev Endocrinol 2020; 16(12): 697–716
https://doi.org/10.1038/s41574-020-00418-5
pmid: 33067545
|
5 |
YS Lee, J Wollam, JM Olefsky. An integrated view of immunometabolism. Cell 2018; 172(1-2): 22–40
https://doi.org/10.1016/j.cell.2017.12.025
pmid: 29328913
|
6 |
RP Goodman, AL Markhard, H Shah, R Sharma, OS Skinner, CB Clish, A Deik, A Patgiri, YH Hsu, R Masia, HL Noh, S Suk, O Goldberger, JN Hirschhorn, G Yellen, JK Kim, VK Mootha. Hepatic NADH reductive stress underlies common variation in metabolic traits. Nature 2020; 583(7814): 122–126
https://doi.org/10.1038/s41586-020-2337-2
pmid: 32461692
|
7 |
Y Zhang, J Ye. Mitochondrial inhibitor as a new class of insulin sensitizer. Acta Pharm Sin B 2012; 2(4): 341–349
https://doi.org/10.1016/j.apsb.2012.06.010
pmid: 23710432
|
8 |
PJ Randle, PB Garland, CN Hales, EA Newsholme. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963; 281(7285): 785–789
https://doi.org/10.1016/S0140-6736(63)91500-9
pmid: 13990765
|
9 |
EA Hernández, S Kahl, A Seelig, P Begovatz, M Irmler, Y Kupriyanova, B Nowotny, P Nowotny, C Herder, C Barosa, F Carvalho, J Rozman, S Neschen, JG Jones, J Beckers, MH de Angelis, M Roden. Acute dietary fat intake initiates alterations in energy metabolism and insulin resistance. J Clin Invest 2017; 127(2): 695–708
https://doi.org/10.1172/JCI89444
pmid: 28112681
|
10 |
JH Lee, Y Zhang, Z Zhao, X Ye, X Zhang, H Wang, J Ye. Intracellular ATP in balance of pro- and anti-inflammatory cytokines in adipose tissue with and without tissue expansion. Int J Obes 2017; 41(4): 645–651
https://doi.org/10.1038/ijo.2017.3
pmid: 28074058
|
11 |
Y Zhang, Z Zhao, B Ke, L Wan, H Wang, J Ye. Induction of posttranslational modifications of mitochondrial proteins by ATP contributes to negative regulation of mitochondrial function. PLoS One 2016; 11(3): e0150454
https://doi.org/10.1371/journal.pone.0150454
pmid: 26930489
|
12 |
S Qian, L Ma, S Peng, Y Xu, K Wu, S Shen, X Zhang, Y Sun, J Ye. ATP reduces mitochondrial MECR protein in liver of diet-induced obese mice in mechanism of insulin resistance. Biosci Rep 2020; 40(6): BSR20200665
https://doi.org/10.1042/BSR20200665
pmid: 32440681
|
13 |
J Le, X Zhang, W Jia, Y Zhang, J Luo, Y Sun, J Ye. Regulation of microbiota-GLP1 axis by sennoside A in diet-induced obese mice. Acta Pharm Sin B 2019; 9(4): 758–768
https://doi.org/10.1016/j.apsb.2019.01.014
pmid: 31384536
|
14 |
Y Sun, C Jin, X Zhang, W Jia, J Le, J Ye. Restoration of GLP-1 secretion by Berberine is associated with protection of colon enterocytes from mitochondrial overheating in diet-induced obese mice. Nutr Diabetes 2018; 8(1): 53
https://doi.org/10.1038/s41387-018-0061-x
pmid: 30250193
|
15 |
KA Coughlan, RJ Valentine, NB Ruderman, AK Saha. Nutrient excess in AMPK downregulation and insulin resistance. J Endocrinol Diabetes Obes 2013; 1(1): 1008
pmid: 26120590
|
16 |
NB Ruderman, D Carling, M Prentki, JM Cacicedo. AMPK, insulin resistance, and the metabolic syndrome. J Clin Invest 2013; 123(7): 2764–2772
https://doi.org/10.1172/JCI67227
pmid: 23863634
|
17 |
D Garcia, RJ Shaw. AMPK: mechanisms of cellular energy sensing and restoration of metabolic balance. Mol Cell 2017; 66(6): 789–800
https://doi.org/10.1016/j.molcel.2017.05.032
pmid: 28622524
|
18 |
P Jiang, L Ren, L Zhi, Z Yu, F Lv, F Xu, W Peng, X Bai, K Cheng, L Quan, X Zhang, X Wang, Y Zhang, D Yang, X Hu, RP Xiao. Negative regulation of AMPK signaling by high glucose via E3 ubiquitin ligase MG53. Mol Cell 2021; 81(3): 629–637.e5
https://doi.org/10.1016/j.molcel.2020.12.008
pmid: 33400924
|
19 |
SH Um, D D’Alessio, G Thomas. Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1. Cell Metab 2006; 3(6): 393–402
https://doi.org/10.1016/j.cmet.2006.05.003
pmid: 16753575
|
20 |
DM Muoio. Metabolic inflexibility: when mitochondrial indecision leads to metabolic gridlock. Cell 2014; 159(6): 1253–1262
https://doi.org/10.1016/j.cell.2014.11.034
pmid: 25480291
|
21 |
TR Koves, JR Ussher, RC Noland, D Slentz, M Mosedale, O Ilkayeva, J Bain, R Stevens, JR Dyck, CB Newgard, GD Lopaschuk, DM Muoio. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab 2008; 7(1): 45–56
https://doi.org/10.1016/j.cmet.2007.10.013
pmid: 18177724
|
22 |
J Qiao, C Chen, D Shangguan, X Mu, S Wang, L Jiang, L Qi. Simultaneous monitoring of mitochondrial temperature and ATP fluctuation using fluorescent probes in living cells. Anal Chem 2018; 90(21): 12553–12558
https://doi.org/10.1021/acs.analchem.8b02496
pmid: 30295464
|
23 |
L Wang, L Yuan, X Zeng, J Peng, Y Ni, JC Er, W Xu, BK Agrawalla, D Su, B Kim, YT Chang. A multisite-binding switchable fluorescent probe for monitoring mitochondrial ATP level fluctuation in live cells. Angew Chem Int Ed Engl 2016; 55(5): 1773–1776
https://doi.org/10.1002/anie.201510003
pmid: 26676712
|
24 |
SN Qian, SQ Peng, XY Zhang, JP Ye. Novel role of intracellular ATP in obesity pathology. Acta Physiol Sin (Sheng Li Xue Bao) 2020; 72(4): 532–538 (in Chinese)
pmid: 32820316
|
25 |
JB Spinelli, MC Haigis. The multifaceted contributions of mitochondria to cellular metabolism. Nat Cell Biol 2018; 20(7): 745–754
https://doi.org/10.1038/s41556-018-0124-1
pmid: 29950572
|
26 |
MP Mollica, S Iossa, G Liverini, S Soboll. Stimulation of oxygen consumption following addition of lipid substrates in liver and skeletal muscle from rats fed a high-fat diet. Metabolism 1999; 48(10): 1230–1235
https://doi.org/10.1016/S0026-0495(99)90260-3
pmid: 10535383
|
27 |
A Català-Niell, ME Estrany, AM Proenza, M Gianotti, I Lladó. Skeletal muscle and liver oxidative metabolism in response to a voluntary isocaloric intake of a high fat diet in male and female rats. Cell Physiol Biochem 2008; 22(1-4): 327–336
https://doi.org/10.1159/000149811
pmid: 18769060
|
28 |
A Roesler, L Kazak. UCP1-independent thermogenesis. Biochem J 2020; 477(3): 709–725
https://doi.org/10.1042/BCJ20190463
pmid: 32059055
|
29 |
D Chiumello, M Gotti, G Vergani. Paracetamol in fever in critically ill patients—an update. J Crit Care 2017; 38: 245–252
https://doi.org/10.1016/j.jcrc.2016.10.021
pmid: 27992852
|
30 |
G Boden, F Jadali, J White, Y Liang, M Mozzoli, X Chen, E Coleman, C Smith. Effects of fat on insulin-stimulated carbohydrate metabolism in normal men. J Clin Invest 1991; 88(3): 960–966
https://doi.org/10.1172/JCI115399
pmid: 1885781
|
31 |
M Roden, TB Price, G Perseghin, KF Petersen, DL Rothman, GW Cline, GI Shulman. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 1996; 97(12): 2859–2865
https://doi.org/10.1172/JCI118742
pmid: 8675698
|
32 |
I Pagel-Langenickel, J Bao, L Pang, MN Sack. The role of mitochondria in the pathophysiology of skeletal muscle insulin resistance. Endocr Rev 2010; 31(1): 25–51
https://doi.org/10.1210/er.2009-0003
pmid: 19861693
|
33 |
DM Muoio. Intramuscular triacylglycerol and insulin resistance: guilty as charged or wrongly accused? Biochim Biophys Acta 2010; 1801(3): 281–288
https://doi.org/10.1016/j.bbalip.2009.11.007
pmid: 19958841
|
34 |
Z Hao, MB Mumphrey, RL Townsend, CD Morrison, H Münzberg, J Ye, HR Berthoud. Reprogramming of defended body weight after Roux-En-Y gastric bypass surgery in diet-induced obese mice. Obesity (Silver Spring) 2016; 24(3): 654–660
https://doi.org/10.1002/oby.21400
pmid: 26847390
|
35 |
RS Khan, F Bril, K Cusi, PN Newsome. Modulation of insulin resistance in nonalcoholic fatty liver disease. Hepatology 2019; 70(2): 711–724
https://doi.org/10.1002/hep.30429
pmid: 30556145
|
36 |
G Rena, DG Hardie, ER Pearson. The mechanisms of action of metformin. Diabetologia 2017; 60(9): 1577–1585
https://doi.org/10.1007/s00125-017-4342-z
pmid: 28776086
|
37 |
N Turner, JY Li, A Gosby, SW To, Z Cheng, H Miyoshi, MM Taketo, GJ Cooney, EW Kraegen, DE James, LH Hu, J Li, JM Ye. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes 2008; 57(5): 1414–1418
https://doi.org/10.2337/db07-1552
pmid: 18285556
|
38 |
J Yin, Z Gao, D Liu, Z Liu, J Ye. Berberine improves glucose metabolism through induction of glycolysis. Am J Physiol Endocrinol Metab 2008; 294(1): E148–E156
https://doi.org/10.1152/ajpendo.00211.2007
pmid: 17971514
|
39 |
RJ Perry, T Kim, XM Zhang, HY Lee, D Pesta, VB Popov, D Zhang, Y Rahimi, MJ Jurczak, GW Cline, DA Spiegel, GI Shulman. Reversal of hypertriglyceridemia, fatty liver disease, and insulin resistance by a liver-targeted mitochondrial uncoupler. Cell Metab 2013; 18(5): 740–748
https://doi.org/10.1016/j.cmet.2013.10.004
pmid: 24206666
|
40 |
RJ Perry, D Zhang, XM Zhang, JL Boyer, GI Shulman. Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats. Science 2015; 347(6227): 1253–1256
https://doi.org/10.1126/science.aaa0672
pmid: 25721504
|
41 |
H Jiang, J Jin, Y Duan, Z Xie, Y Li, A Gao, M Gu, X Zhang, C Peng, C Xia, T Dong, H Li, L Yu, J Tang, F Yang, J Li, J Li. Mitochondrial uncoupling coordinated with PDH activation safely ameliorates hyperglycemia via promoting glucose oxidation. Diabetes 2019; 68(12): 2197–2209
https://doi.org/10.2337/db19-0589
pmid: 31471292
|
42 |
I Luptak, AL Sverdlov, M Panagia, F Qin, DR Pimentel, D Croteau, DA Siwik, JS Ingwall, MM Bachschmid, JA Balschi, WS Colucci. Decreased ATP production and myocardial contractile reserve in metabolic heart disease. J Mol Cell Cardiol 2018; 116: 106–114
https://doi.org/10.1016/j.yjmcc.2018.01.017
pmid: 29409987
|
43 |
MK Hesselink, V Schrauwen-Hinderling, P Schrauwen. Skeletal muscle mitochondria as a target to prevent or treat type 2 diabetes mellitus. Nat Rev Endocrinol 2016; 12(11): 633–645
https://doi.org/10.1038/nrendo.2016.104
pmid: 27448057
|
44 |
S Rovira-Llopis, C Bañuls, N Diaz-Morales, A Hernandez-Mijares, M Rocha, VM Victor. Mitochondrial dynamics in type 2 diabetes: Pathophysiological implications. Redox Biol 2017; 11: 637–645
https://doi.org/10.1016/j.redox.2017.01.013
pmid: 28131082
|
45 |
K Sharma. Mitochondrial hormesis and diabetic complications. Diabetes 2015; 64(3): 663–672
https://doi.org/10.2337/db14-0874
pmid: 25713188
|
46 |
CS Zhang, SA Hawley, Y Zong, M Li, Z Wang, A Gray, T Ma, J Cui, JW Feng, M Zhu, YQ Wu, TY Li, Z Ye, SY Lin, H Yin, HL Piao, DG Hardie, SC Lin. Fructose-1,6-bisphosphate and aldolase mediate glucose sensing by AMPK. Nature 2017; 548(7665): 112–116
https://doi.org/10.1038/nature23275
pmid: 28723898
|
47 |
A González, MN Hall, SC Lin, DG Hardie. AMPK and TOR: the yin and yang of cellular nutrient sensing and growth control. Cell Metab 2020; 31(3): 472–492
https://doi.org/10.1016/j.cmet.2020.01.015
pmid: 32130880
|
48 |
S Herzig, RJ Shaw. AMPK: guardian of metabolism and mitochondrial homeostasis. Nat Rev Mol Cell Biol 2018; 19(2): 121–135
https://doi.org/10.1038/nrm.2017.95
pmid: 28974774
|
49 |
DG Hardie, BE Schaffer, A Brunet. AMPK: an energy-sensing pathway with multiple inputs and outputs. Trends Cell Biol 2016; 26(3): 190–201
https://doi.org/10.1016/j.tcb.2015.10.013
pmid: 26616193
|
50 |
B Viollet, F Andreelli, SB Jørgensen, C Perrin, A Geloen, D Flamez, J Mu, C Lenzner, O Baud, M Bennoun, E Gomas, G Nicolas, JF Wojtaszewski, A Kahn, D Carling, FC Schuit, MJ Birnbaum, EA Richter, R Burcelin, S Vaulont. The AMP-activated protein kinase α2 catalytic subunit controls whole-body insulin sensitivity. J Clin Invest 2003; 111(1): 91–98
https://doi.org/10.1172/JCI16567
pmid: 12511592
|
51 |
T Valero. Mitochondrial biogenesis: pharmacological approaches. Curr Pharm Des 2014; 20(35): 5507–5509
https://doi.org/10.2174/138161282035140911142118
pmid: 24606795
|
52 |
BB Lowell, GI Shulman. Mitochondrial dysfunction and type 2 diabetes. Science 2005; 307(5708): 384–387
https://doi.org/10.1126/science.1104343
pmid: 15662004
|
53 |
DE Kelley, LJ Mandarino. Fuel selection in human skeletal muscle in insulin resistance: a reexamination. Diabetes 2000; 49(5): 677–683
https://doi.org/10.2337/diabetes.49.5.677
pmid: 10905472
|
54 |
J Ye. Role of insulin in the pathogenesis of free fatty acid-induced insulin resistance in skeletal muscle. Endocr Metab Immune Disord Drug Targets 2007; 7(1): 65–74
https://doi.org/10.2174/187153007780059423
pmid: 17346204
|
55 |
J Zhang, Z Gao, J Yin, MJ Quon, J Ye. S6K directly phosphorylates IRS-1 on Ser-270 to promote insulin resistance in response to TNF-α signaling through IKK2. J Biol Chem 2008; 283(51): 35375–35382
https://doi.org/10.1074/jbc.M806480200
pmid: 18952604
|
56 |
CB Newgard, J An, JR Bain, MJ Muehlbauer, RD Stevens, LF Lien, AM Haqq, SH Shah, M Arlotto, CA Slentz, J Rochon, D Gallup, O Ilkayeva, BR Wenner, WS Yancy Jr, H Eisenson, G Musante, RS Surwit, DS Millington, MD Butler, LP Svetkey. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 2009; 9(4): 311–326
https://doi.org/10.1016/j.cmet.2009.02.002
pmid: 19356713
|
57 |
CS Zhang, B Jiang, M Li, M Zhu, Y Peng, YL Zhang, YQ Wu, TY Li, Y Liang, Z Lu, G Lian, Q Liu, H Guo, Z Yin, Z Ye, J Han, JW Wu, H Yin, SY Lin, SC Lin. The lysosomal v-ATPase-Ragulator complex is a common activator for AMPK and mTORC1, acting as a switch between catabolism and anabolism. Cell Metab 2014; 20(3): 526–540
https://doi.org/10.1016/j.cmet.2014.06.014
pmid: 25002183
|
58 |
PB Dennis, A Jaeschke, M Saitoh, B Fowler, SC Kozma, G Thomas. Mammalian TOR: a homeostatic ATP sensor. Science 2001; 294(5544): 1102–1105
https://doi.org/10.1126/science.1063518
pmid: 11691993
|
59 |
BE Corkey. Banting lecture 2011: hyperinsulinemia: cause or consequence? Diabetes 2012; 61(1): 4–13
https://doi.org/10.2337/db11-1483
pmid: 22187369
|
60 |
MP Czech. Insulin action and resistance in obesity and type 2 diabetes. Nat Med 2017; 23(7): 804–814
https://doi.org/10.1038/nm.4350
pmid: 28697184
|
61 |
MM Page, JD Johnson. Mild suppression of hyperinsulinemia to treat obesity and insulin resistance. Trends Endocrinol Metab 2018; 29(6): 389–399
https://doi.org/10.1016/j.tem.2018.03.018
pmid: 29665988
|
62 |
KA Erion, BE Corkey. Hyperinsulinemia: a cause of obesity? Curr Obes Rep 2017; 6(2): 178–186
https://doi.org/10.1007/s13679-017-0261-z
pmid: 28466412
|
63 |
MH Shanik, Y Xu, J Skrha, R Dankner, Y Zick, J Roth. Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse? Diabetes Care 2008; 31(Suppl 2): S262–S268
https://doi.org/10.2337/dc08-s264
pmid: 18227495
|
64 |
AE Mehran, NM Templeman, GS Brigidi, GE Lim, KY Chu, X Hu, JD Botezelli, A Asadi, BG Hoffman, TJ Kieffer, SX Bamji, SM Clee, JD Johnson. Hyperinsulinemia drives diet-induced obesity independently of brain insulin production. Cell Metab 2012; 16(6): 723–737
https://doi.org/10.1016/j.cmet.2012.10.019
pmid: 23217255
|
65 |
JE Campbell, CB Newgard. Mechanisms controlling pancreatic islet cell function in insulin secretion. Nat Rev Mol Cell Biol 2021; 22(2): 142–158
https://doi.org/10.1038/s41580-020-00317-7
pmid: 33398164
|
66 |
GI Smith, DC Polidori, M Yoshino, ML Kearney, BW Patterson, B Mittendorfer, S Klein. Influence of adiposity, insulin resistance, and intrahepatic triglyceride content on insulin kinetics. J Clin Invest 2020; 130(6): 3305–3314
https://doi.org/10.1172/JCI136756
pmid: 32191646
|
67 |
SL Gray, C Donald, A Jetha, SD Covey, TJ Kieffer. Hyperinsulinemia precedes insulin resistance in mice lacking pancreatic β-cell leptin signaling. Endocrinology 2010; 151(9): 4178–4186
https://doi.org/10.1210/en.2010-0102
pmid: 20631001
|
68 |
G Burnstock. Purinergic signalling in endocrine organs. Purinergic Signal 2014; 10(1): 189–231
https://doi.org/10.1007/s11302-013-9396-x
pmid: 24265070
|
69 |
A Hazama, S Hayashi, Y Okada. Cell surface measurements of ATP release from single pancreatic β cells using a novel biosensor technique. Pflugers Arch 1998; 437(1): 31–35
https://doi.org/10.1007/s004240050742
pmid: 9817782
|
70 |
JC Hutton, EJ Penn, M Peshavaria. Low-molecular-weight constituents of isolated insulin-secretory granules. Bivalent cations, adenine nucleotides and inorganic phosphate. Biochem J 1983; 210(2): 297–305
https://doi.org/10.1042/bj2100297
pmid: 6344863
|
71 |
S Soberanes, AV Misharin, A Jairaman, L Morales-Nebreda, AC McQuattie-Pimentel, T Cho, RB Hamanaka, AY Meliton, PA Reyfman, JM Walter, CI Chen, M Chi, S Chiu, FJ Gonzalez-Gonzalez, M Antalek, H Abdala-Valencia, SE Chiarella, KA Sun, PS Woods, AJ Ghio, M Jain, H Perlman, KM Ridge, RI Morimoto, JI Sznajder, WE Balch, SM Bhorade, A Bharat, M Prakriya, NS Chandel, GM Mutlu, GRS Budinger. Metformin targets mitochondrial electron transport to reduce air-pollution-induced thrombosis. Cell Metab 2019; 29(2): 335–347.e5
pmid: 30318339
|
72 |
X Yang, Z Xu, C Zhang, Z Cai, J Zhang. Metformin, beyond an insulin sensitizer, targeting heart and pancreatic β cells. Biochim Biophys Acta Mol Basis Dis 2017; 1863(8): 1984–1990
https://doi.org/10.1016/j.bbadis.2016.09.019
pmid: 27702625
|
73 |
BA Kefas, Y Cai, K Kerckhofs, Z Ling, G Martens, H Heimberg, D Pipeleers, M Van de Casteele. Metformin-induced stimulation of AMP-activated protein kinase in β-cells impairs their glucose responsiveness and can lead to apoptosis. Biochem Pharmacol 2004; 68(3): 409–416
https://doi.org/10.1016/j.bcp.2004.04.003
pmid: 15242807
|
74 |
J Carpentier, AS Luyckx, PJ Lefebvre. Influence of metformin on arginine-induced glucagon secretion in human diabetes. Diabete Metab 1975; 1: 23–28
pmid: 1234063
|
75 |
X Wei, B Ke, Z Zhao, X Ye, Z Gao, J Ye. Regulation of insulin degrading enzyme activity by obesity-associated factors and pioglitazone in liver of diet-induced obese mice. PLoS One 2014; 9(4): e95399
https://doi.org/10.1371/journal.pone.0095399
pmid: 24740421
|
76 |
YH Lee, MY Wang, XX Yu, RH Unger. Glucagon is the key factor in the development of diabetes. Diabetologia 2016; 59(7): 1372–1375
https://doi.org/10.1007/s00125-016-3965-9
pmid: 27115412
|
77 |
B Finan, ME Capozzi, JE Campbell. Repositioning glucagon action in the physiology and pharmacology of diabetes. Diabetes 2020; 69(4): 532–541
https://doi.org/10.2337/dbi19-0004
pmid: 31178432
|
78 |
BE Dunning, JE Gerich. The role of α-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev 2007; 28(3): 253–283
https://doi.org/10.1210/er.2006-0026
pmid: 17409288
|
79 |
RA Miller, Q Chu, J Xie, M Foretz, B Viollet, MJ Birnbaum. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 2013; 494(7436): 256–260
https://doi.org/10.1038/nature11808
pmid: 23292513
|
80 |
JH Pettus, D D’Alessio, JP Frias, EG Vajda, JD Pipkin, J Rosenstock, G Williamson, MA Zangmeister, L Zhi, KB Marschke. Efficacy and safety of the glucagon receptor antagonist RVT-1502 in type 2 diabetes uncontrolled on metformin monotherapy: a 12-week dose-ranging study. Diabetes Care 2020; 43(1): 161–168
https://doi.org/10.2337/dc19-1328
pmid: 31694861
|
81 |
PE Cryer. Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology 2012; 153(3): 1039–1048
https://doi.org/10.1210/en.2011-1499
pmid: 22166985
|
82 |
A Wendt, B Birnir, K Buschard, J Gromada, A Salehi, S Sewing, P Rorsman, M Braun. Glucose inhibition of glucagon secretion from rat alpha-cells is mediated by GABA released from neighboring β-cells. Diabetes 2004; 53(4): 1038–1045
https://doi.org/10.2337/diabetes.53.4.1038
pmid: 15047619
|
83 |
O Cabrera, MC Jacques-Silva, S Speier, SN Yang, M Köhler, A Fachado, E Vieira, JR Zierath, R Kibbey, DM Berman, NS Kenyon, C Ricordi, A Caicedo, PO Berggren. Glutamate is a positive autocrine signal for glucagon release. Cell Metab 2008; 7(6): 545–554
https://doi.org/10.1016/j.cmet.2008.03.004
pmid: 18522835
|
84 |
AD Elliott, A Ustione, DW Piston. Somatostatin and insulin mediate glucose-inhibited glucagon secretion in the pancreatic α-cell by lowering cAMP. Am J Physiol Endocrinol Metab 2015; 308(2): E130–E143
https://doi.org/10.1152/ajpendo.00344.2014
pmid: 25406263
|
85 |
M Omar-Hmeadi, PE Lund, NR Gandasi, A Tengholm, S Barg. Paracrine control of α-cell glucagon exocytosis is compromised in human type-2 diabetes. Nat Commun 2020; 11(1): 1896
https://doi.org/10.1038/s41467-020-15717-8
pmid: 32312960
|
86 |
R Liu, J Hong, X Xu, Q Feng, D Zhang, Y Gu, J Shi, S Zhao, W Liu, X Wang, H Xia, Z Liu, B Cui, P Liang, L Xi, J Jin, X Ying, X Wang, X Zhao, W Li, H Jia, Z Lan, F Li, R Wang, Y Sun, M Yang, Y Shen, Z Jie, J Li, X Chen, H Zhong, H Xie, Y Zhang, W Gu, X Deng, B Shen, X Xu, H Yang, G Xu, Y Bi, S Lai, J Wang, L Qi, L Madsen, J Wang, G Ning, K Kristiansen, W Wang. Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention. Nat Med 2017; 23(7): 859–868
https://doi.org/10.1038/nm.4358
pmid: 28628112
|
87 |
M Simonson, Y Boirie, C Guillet. Protein, amino acids and obesity treatment. Rev Endocr Metab Disord 2020; 21(3): 341–353
https://doi.org/10.1007/s11154-020-09574-5
pmid: 32827096
|
88 |
G Burnstock, D Gentile. The involvement of purinergic signalling in obesity. Purinergic Signal 2018; 14(2): 97–108
https://doi.org/10.1007/s11302-018-9605-8
pmid: 29619754
|
89 |
L Antonioli, C Blandizzi, P Pacher, G Haskó. The purinergic system as a pharmacological target for the treatment of immune-mediated inflammatory diseases. Pharmacol Rev 2019; 71(3): 345–382
https://doi.org/10.1124/pr.117.014878
pmid: 31235653
|
90 |
G Giacovazzo, P Fabbrizio, S Apolloni, R Coccurello, C Volonté. Stimulation of P2X7 enhances whole body energy metabolism in mice. Front Cell Neurosci 2019; 13: 390
https://doi.org/10.3389/fncel.2019.00390
pmid: 31496939
|
91 |
S Sun, S Xia, Y Ji, S Kersten, L Qi. The ATP-P2X7 signaling axis is dispensable for obesity-associated inflammasome activation in adipose tissue. Diabetes 2012; 61(6): 1471–1478
https://doi.org/10.2337/db11-1389
pmid: 22415881
|
92 |
R Pérez-Sen, R Gómez-Villafuertes, F Ortega, J Gualix, EG Delicado, MT Miras-Portugal. An update on P2Y13 receptor signalling and function. Adv Exp Med Biol 2017; 1051: 139–168
https://doi.org/10.1007/5584_2017_91
pmid: 28815513
|
93 |
X Cao, X Ye, S Zhang, L Wang, Y Xu, S Peng, Y Zhou, Y Peng, J Li, X Zhang, X Han, H Huang, W Jia, J Ye. ADP induces blood glucose through direct and indirect mechanisms in promotion of hepatic gluconeogenesis by elevation of NADH. Front Endocrinol 2021; 12: 663530
https://doi.org/10.3389/fendo.2021.663530
|
94 |
S Amisten, S Meidute-Abaraviciene, C Tan, B Olde, I Lundquist, A Salehi, D Erlinge. ADP mediates inhibition of insulin secretion by activation of P2Y13 receptors in mice. Diabetologia 2010; 53(9): 1927–1934
https://doi.org/10.1007/s00125-010-1807-8
pmid: 20526761
|
95 |
K Enjyoji, K Kotani, C Thukral, B Blumel, X Sun, Y Wu, M Imai, D Friedman, E Csizmadia, W Bleibel, BB Kahn, SC Robson. Deletion of cd39/entpd1 results in hepatic insulin resistance. Diabetes 2008; 57(9): 2311–2320
https://doi.org/10.2337/db07-1265
pmid: 18567823
|
96 |
FJ Jacques, TM Silva, FE da Silva, IM Ornelas, ALM Ventura. Nucleotide P2Y13-stimulated phosphorylation of CREB is required for ADP-induced proliferation of late developing retinal glial progenitors in culture. Cell Signal 2017; 35: 95–106
https://doi.org/10.1016/j.cellsig.2017.03.019
pmid: 28347874
|
97 |
D Blom, TT Yamin, MF Champy, M Selloum, E Bedu, E Carballo-Jane, L Gerckens, S Luell, R Meurer, J Chin, J Mudgett, O Puig. Altered lipoprotein metabolism in P2Y13 knockout mice. Biochim Biophys Acta 2010; 1801(12): 1349–1360
https://doi.org/10.1016/j.bbalip.2010.08.013
pmid: 20817122
|
98 |
KF Petersen, D Befroy, S Dufour, J Dziura, C Ariyan, DL Rothman, L DiPietro, GW Cline, GI Shulman. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 2003; 300(5622): 1140–1142
https://doi.org/10.1126/science.1082889
pmid: 12750520
|
99 |
RM Reznick, H Zong, J Li, K Morino, IK Moore, HJ Yu, ZX Liu, J Dong, KJ Mustard, SA Hawley, D Befroy, M Pypaert, DG Hardie, LH Young, GI Shulman. Aging-associated reductions in AMP-activated protein kinase activity and mitochondrial biogenesis. Cell Metab 2007; 5(2): 151–156
https://doi.org/10.1016/j.cmet.2007.01.008
pmid: 17276357
|
100 |
N Houstis, ED Rosen, ES Lander. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006; 440(7086): 944–948
https://doi.org/10.1038/nature04634
pmid: 16612386
|
101 |
KS Nair, ML Bigelow, YW Asmann, LS Chow, JM Coenen-Schimke, KA Klaus, ZK Guo, R Sreekumar, BA Irving. Asian Indians have enhanced skeletal muscle mitochondrial capacity to produce ATP in association with severe insulin resistance. Diabetes 2008; 57(5): 1166–1175
https://doi.org/10.2337/db07-1556
pmid: 18285554
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|